Form 4: Pacira CFO Sells Shares Under Pre-Arranged 10b5-1 Plan

Pacira BioSciences' Chief Financial Officer, Shawn Cross, sold 12,060 shares of common stock at $22.09 per share as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Shawn Cross, Chief Financial Officer of Pacira BioSciences, Inc. (PCRX), reported a sale of common stock.
• The transaction involved the disposition of 12,060 shares of common stock.
• The shares were sold at a price of $22.09 per share.
• The sale was executed on November 10, 2025.
• Following this transaction, Shawn Cross directly beneficially owns 56,250 shares of common stock.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan, which was previously adopted by the reporting person.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be seen negatively, the fact that it was executed under a pre-arranged Rule 10b5-1 trading plan suggests it was for personal financial planning (e.g., diversification, liquidity) rather than a reaction to new negative company-specific information. This mitigates any strong negative signal.

Negatives

• An insider, the Chief Financial Officer, sold a portion of their holdings, which can sometimes be perceived as a lack of confidence, although this is mitigated by the pre-arranged 10b5-1 plan.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is specific to Pacira BioSciences and does not directly reflect broader industry trends or competitive dynamics. Insider sales under 10b5-1 plans are common across various industries for personal financial planning.

Stakeholder Impact

• Shareholders may note the insider sale, but the pre-arranged nature of the 10b5-1 plan typically reduces concerns about its signaling effect regarding the company's future performance.

Key Dates

Recommendation

The sale by the CFO was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance and not necessarily based on new material non-public information. Such routine sales for diversification or liquidity purposes do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this transaction does not provide new information to alter an existing investment thesis.

Keywords

Pacira BioSciences, PCRX, Shawn Cross, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan